(Bloomberg) — Insmed Inc. shares more than doubled after the company’s experimental drug reduced episodes of worsening symptoms in a final-stage study of patients with a rare lung condition. Most Read from Bloomberg Patients with bronchiectasis who received Insmed’s brensocatib had fewer exacerbations than those who got a placebo in the yearlong study, New Jersey-based […]